Author
F. P. Veras
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2022 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 41 mutual co-author links6 papers
Recent·Most cited
Targeting C5aR1 signaling reduced neutrophil extracellular traps and ameliorates COVID-19 pathology
B. M. Silva, F. P. Veras, G. Gomes, S. Cambier, G. Silva, A. Quadros, D. Caetite, D. Nascimento, C. Silva, J. Silva, S. Damasceno, A. Schneider, F. Beretta, S. Batah, I. Castro, , T. M. Cunha
This study shows that inhibiting C5aR1 signaling reduces neutrophil extracellular traps and improves lung pathology in COVID-19.
bioRxiv · Jul 3, 2022Immunology
Targeting Neutrophils Extracellular Traps (NETs) reduces multiple organ injury in a COVID-19 mouse model
F. P. Veras, G. F. Gomes, B. M. Silva, C. Almeida, C. M. Silva, A. H. Schneider, E. S. Corneo, C. S. Bonilha, S. S. Batah, R. P. Martins, E. Arruda, A. T. Fabro, J. C. A. Alves-Filho, T. M. Cunha, F. Q. Cunha
This study shows that DNase I treatment reduces NETs and organ injury in a COVID-19 mouse model.
bioRxiv · Apr 27, 2022Pharmacology & Toxicology
Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice
A. C. Puhl, G. F. Gomes, S. Damasceno, E. J. Fritch, J. A. Levi, N. J. Johnson, F. Scholle, L. Premkumar, B. L. Hurst, F. LeeMontiel, F. P. Veras, S. S. Batah, A. T. Fabro, N. J. Moorman, B. Yount, , S. Ekins
This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.
bioRxiv · Dec 16, 2021 · PreprintImmunology
Pyronaridine Protects Against SARS-CoV-2 in Mouse
A. C. Puhl, G. F. Gomes, S. Damasceno, A. S. de Godoy, G. D. Noske, A. M. Nakamura, V. O. Gawrijuk, R. S. Fernandes, N. Monakhova, O. Riabova, T. R. Lane, V. Makarov, F. P. Veras, S. S. Batah, A. T. Fabro, , S. Ekins
Pyronaridine reduces SARS-CoV-2 viral load and lung pathology in mice, with in vitro inhibition of viral PLpro and host kinase CAMK1.
bioRxiv · Sep 30, 2021 · PreprintPharmacology & Toxicology
Infection of human lymphomononuclear cells by SARS-CoV-2
M. C. Pontelli, I. A. Castro, R. B. Martins, F. P. Veras, L. La Serra, D. C. Nascimento, R. S. Cardoso, R. Rosales, T. M. Lima, J. P. Souza, D. B. Caetite, M. H. Lima, J. T. Kawahisa, M. C. Giannini, L. P. Bonjorno, , E. Arruda
This study investigates SARS-CoV-2 infection of human lymphomononuclear cells in vitro and in vivo, finding that monocytes, B cells, and T cells are susceptible to infection and viral replication.
bioRxiv · Jul 28, 2020Microbiology